Kevin S Eisenfrats

Executive Officer, Director, Promoter at Contraline.

Raised on Contraline filings

$55.8M

of $115.9M offered across 1 Form D filing

Form D filings: 1
Teammates: 4
Last filing: Jun 10, 2026

Company

Biotech · Charlottesville, VA

Hydrogel implant for reversible male contraception

Hydrogel implant for reversible male contraception

Investors: 77
Still open: $60.1M

Investors: 77
Sector: Biotech
HQ: Charlottesville, VA

Contraline filings

Contraline Form D filings
Filed	Security	Sold of offered	Filing
Jun 10, 2026	Equity	$55.8M/ $115.9M	Form D

EquityFiled Jun 10, 2026Form D
$55.8M/ $115.9M

Works with

Also named on Contraline filings

Kevin L EisenfratsChief Executive Officer, Form D signerForm D signer Iris Van Alderwerelt van RosenburghDirector Martin J EmersonDirector Gurdane BhutaniDirector